An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center.
Lingling FuJie MaHao GuJingyao MaYunyun WeiZhengping ChenRunhui WuPublished in: Pediatric blood & cancer (2021)
The escalating strategy for children SCITP showed an effective improvement rate with 36.7% remission and 68.2% SR, and 30% could benefit and retain SR from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low-dose rituximab.